naion and semaglutide use of semaglutide is associated to an increased risk of NAION - NAION semaglutideReddit Semaglutide showed a significant ROR and PRR for NAION Understanding the Association Between Semaglutide and NAION: A Comprehensive Review

NAIONMounjaro Semaglutide, a widely recognized GLP-1 receptor agonist, has demonstrated significant efficacy in managing type 2 diabetes and promoting weight loss作者：CX Cai·2025·被引用次数：86—The risk of NAION was higher among semaglutide usersregardless of prior medication exposure compared with empagliflozin (both definitions) and .... However, recent research has brought to light a potential, albeit very rare, association between semaglutide use and Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). This article delves into the available evidence, exploring the nuances of this association, its potential implications, and what healthcare professionals and patients should consider.

What is NAION and its connection to Semaglutide?

NAION is a critical condition affecting the optic nerve, characterized by sudden vision loss, typically in one eye作者：AY Hsu·2025·被引用次数：2—Their findings also indicated anincreased risk of NAION among users of semaglutide, as well as exenatide, another GLP-1 receptor agonist. This .... It occurs due to impaired blood flow to the optic nerve headIncreased vision impairment reports linked to semaglutide - PMC - NIH. While the exact etiology of NAION is not fully understood, several predisposing factors have been identified, including age, diabetes, cardiovascular disease, and sleep apnea.

Recent studies, including a significant matched cohort study involving 16,827 patients, have indicated a higher risk of NAION in patients prescribed semaglutide compared to those on other medications. Further analysis suggests that semaglutide treatment may be very rarely associated with NAION, potentially affecting up to 1 in 10,000 users. Some research indicates that the risk of NAION was higher among semaglutide users, with one study suggesting it was more than three times higher for patients taking semaglutide than for those on non-GLP-1 drugs. For patients with diabetes, the risk may be around four times higher, and for individuals with obesity on semaglutide, it could be more than seven times the risk. Another study concluded that use of once-weekly semaglutide more than doubles the risk of NAION, and that semaglutide independently more than doubled the risk of NAION.Increased vision impairment reports linked to semaglutide - PMC - NIH

It's important to note that the European Medicines Agency (EMA) has concluded that NAION is a very rare side effect of semaglutideSemaglutide, type 2 diabetes, and the risk of nonarteritic .... However, given the potentially irreversible nature of NAION, the European Medicines Agency (EMA) has recommended that treatment with semaglutide should be stopped if NAION is confirmedBilateral Non-Arteritic Anterior Ischemic Optic Neuropathy ....

Exploring the Evidence and Potential Mechanisms

Several studies have investigated the link between semaglutide and NAION. A retrospective study analyzing GLP-1 Receptor Agonists and their impact on NAION risk found that semaglutide showed a significant relative risk (ROR) and proportional reporting ratio (PRR) for NAION, suggesting a potentially stronger association compared to other GLP-1 receptor agonists.Does Semaglutide Increase the Risk of Nonarteritic ... This research suggests a link between semaglutide and NAION, even when considering prior medication exposure.

However, some multinational cohort studies have not found semaglutide to be associated with an increased risk of NAION.14小时前—People with diabetes on semaglutide:around four times the risk of NAION; People with obesity on semaglutide: more than seven times the risk. This highlights the ongoing nature of research and the need for careful interpretation of findings. Factors such as patient populations, study methodologies, and the definition of NAION itself can influence the results作者：M Azab·2025·被引用次数：22—Semaglutide showed a significant ROR and PRR for NAION, suggesting a stronger association compared to other GLP-1 receptor agonists. The findings suggest a .... The cumulative five-year risk of NAION and Ischemic Optic Neuropathy (ION) in patients on semaglutide has been reported as 0.2025年6月6日—IfNAIONis confirmed, treatment withsemaglutideshould be stopped. More about the medicines.Semaglutide, a GLP-1 receptor agonist, is the ...065% and 0.08%, respectively. For individuals with high BMI prescribed semaglutide, the risks of NAION and ION after two years were 0.038% and 0.404%, respectively.

While the precise mechanism by which semaglutide might be associated with NAION remains unclear, ongoing research aims to elucidate this. Some theories propose that semaglutide’s effects on vascular function or metabolic changes could play a role.

Important Considerations for Patients and Clinicians

For individuals prescribed semaglutide, understanding the potential risks is crucial. While the incidence of NAION in semaglutide users is estimated at 14.2024年10月29日—...NAION(HR 7,64; P<0.001). Kesimpulan: Studi ini menunjukkan adanya hubungan antarasemaglutidedanNAION. Mengingat bahwa ini adalah studi ...5 per 100,000 person-years, clinicians and patients should be counseled on the rare but evident increased risk of NAION after semaglutide initiation2025年1月12日—...semaglutide doubles the five-year risk of NAION. In this comment, the new evidence is discussed, along with practical implications for type ....

If you are taking semaglutide and experience sudden vision changes, such as blurred vision, loss of peripheral vision, or visual field defects, it is imperative to seek immediate medical attention. Prompt diagnosis and intervention are vital for managing NAION and potentially mitigating further vision loss.

Semaglutide should be used judiciously, and healthcare providers should carefully weigh the benefits against potential risks, especially in individuals with pre-existing risk factors for NAION. Discussions about semaglutide and NAION should be a part of informed consent and ongoing patient care2024年7月25日—The etiology is unknown, butNAION has been associated with age, diabetes, cardiovascular disease, and sleep apnea. After noting anecdotally ....

Related searches such as NAION GLP1, NAION semaglutide Reddit, NAION Mounjaro, NAION tirzepatide, Semaglutide NAION mechanism, NAION symptoms, and Semaglutide NAION risk reflect the growing interest and concern surrounding this topic. It's also worth noting that discussions around GLP-1 NAION lawsuit indicate a developing legal landscape surrounding these potential adverse effects.

In conclusion, while semaglutide offers significant therapeutic advantages, a very rare association with NAION has been reported. Continued research, vigilant patient monitoring, and open communication between healthcare providers and patients are essential to ensure the safe and effective use of this medication.PRAC concludes eye condition NAION is a very rare side ...